However, most evidence for AMPs in IBD comes from acute DSS models with heterogeneous preparations, and neither chronic/relapsing colitis nor combination therapy with standard IBD drugs has been systematically evaluated. This evidence concerns the gene ADSL and inflammatory bowel disease.